ScHARR-TAG, which is the NICE Evidence Review Group based within HEDS, has been allocated two new topics:
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis (NICE STA).
NIOX MINO for the measurement of exhaled nitric oxide concentration for
the diagnosis and management of inflammatory airway disease (NICE DAR)
This is part of a reorganisation of topics across ERGs within the groups which has also led to ScHARR-TAG passing on two appraisals to other groups. These are:
Acute coronary syndrome - rivaroxaban [ID532]
Leukaemia (acute myeloid ) - decitabine [ID355]
Finally, ScHARR-TAG has picked up one further review for NETSCC, which is outside the NICE appraisal process. This is cytisine for smoking cessation.
